The goal of this program is to improve management of bladder cancer using novel approaches and use of trimodality therapy in treatment of bladder cancer. After hearing and assimilating this program, the clinician will be better able to:
1. Differentiate between classic MVAC and dose-dependent MVAC.
2. Explain the significance of cisplatin ineligibility in the KEYNOTE-052 trial.
3. Cite the benefits of atezolizumab in management of metastatic urothelial cancer based on evidence from IMvigor210.
4. Optimize the treatment of bladder cancer depending on patient characteristics.
5. Administer newer less invasive therapies in patients with bladder cancer.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Urology
- Start Date: 2022-05-04 05:00:00
- End Date: 2022-05-04 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest